Aspirin for primary prevention of vascular disease in people with diabetes

BMJ (Online)

Volumn 339, Issue 7732, 2009, Pages 1210-

  Haynes, Richard ^a   Bowman, Louise ^a   Armitage, Jane ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE DISTRIBUTION; BLEEDING; CARDIOVASCULAR RISK; DECISION MAKING; DIABETES MELLITUS; EDITORIAL; GENDER; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MORTALITY; OBESITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK REDUCTION; SMOKING; STROKE; VASCULAR DISEASE;

ASPIRIN; CARDIOVASCULAR AGENTS; DIABETIC ANGIOPATHIES; HUMANS; PRIMARY PREVENTION;

EID: 71749088596     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b4596     Document Type: Editorial

References (12)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431[Abstract]
2. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524.[Medline]
3. Cholesterol Treatment Trialists' (CTTC) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278[CrossRef][Web of Science][Medline]
4. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535[CrossRef][Web of Science][Medline] (Pubitemid 37410190)
5. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772[CrossRef][Web of Science] [Medline]
6. De Berardis G, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531.[Abstract/Free Full Text]
7. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 5):1-52.[Abstract/Free Full Text]
8. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.[Abstract/Free Full Text]
9. Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849- 1860[CrossRef][Web of Science][Medline]
10. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006;4:22.[CrossRef][Medline] (Pubitemid 44524375)
11. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007;8:21.[CrossRef][Medline] (Pubitemid 47570624)
12. ASCEND Collaborative Group. A study of cardiovascular events in diabetes. www.ctsu.ox.ac.uk/ascend.